A24.3 Other melioidosis

Name of the Condition

• Other melioidosis

Summary

Other melioidosis refers to melioidosis presentations that do not fall under the acute/fulminating or localized categories. It is an infectious disease caused by Burkholderia pseudomallei, a bacterium found in soil and water, primarily in tropical regions. The condition can affect various organ systems and may present with a range of clinical manifestations, from mild to severe, depending on the route of exposure and host factors.

Causes

Other melioidosis is caused by Burkholderia pseudomallei, a gram-negative bacterium. Infection occurs through inhalation, ingestion, or skin inoculation of contaminated soil, water, or organic matter. The bacteria can establish localized infections or disseminate systemically, leading to diverse clinical outcomes based on the site of entry and host immune response.

Risk Factors

• Residing in or traveling to tropical regions where Burkholderia pseudomallei is endemic (e.g., Southeast Asia, northern Australia).
• Underlying conditions such as diabetes, chronic lung disease, or immunosuppression, which increase susceptibility to severe disease.
• Occupational or recreational exposure to contaminated environments (e.g., farming, gardening, or contact with soil/water).

Symptoms

• Variable fever patterns (intermittent or persistent)
• Respiratory symptoms (e.g., cough, chest discomfort)
• Skin lesions or abscesses (localized or disseminated)
• Gastrointestinal symptoms (e.g., nausea, abdominal pain)
• Generalized malaise or fatigue
• Possible involvement of specific organs (e.g., liver, spleen, or bones) depending on dissemination.

Diagnosis

Diagnosis is based on clinical suspicion, exposure history, and laboratory testing. Confirmation typically involves culturing Burkholderia pseudomallei from clinical specimens (e.g., blood, sputum, or tissue). Serological tests or molecular methods (e.g., PCR) may support diagnosis, especially in endemic areas. Imaging studies may identify organ involvement or abscesses.

Treatment Options

Treatment involves prolonged antibiotic therapy, often with intravenous agents (e.g., ceftazidime or meropenem) followed by oral eradication therapy (e.g., trimethoprim-sulfamethoxazole with or without doxycycline). Duration depends on disease severity and organ involvement. Adjunctive therapies (e.g., drainage of abscesses) may be necessary for localized infections.

Prognosis and Follow-Up

Prognosis varies with disease severity, host factors, and timeliness of treatment. Severe or disseminated cases carry higher mortality risks. Follow-up includes monitoring for treatment response, recurrence, or complications. Long-term surveillance may be required for chronic or relapsing infections.

Complications

• Organ-specific complications (e.g., pneumonia, sepsis, or abscess formation)
• Chronic infection or relapse
• Secondary bacterial infections due to immunosuppression
• Potential for multi-organ failure in severe cases.

Lifestyle & Prevention

• Avoid contact with contaminated soil or water in endemic areas.
• Use protective gear (e.g., gloves, masks) during high-risk activities.
• Seek prompt medical care for wounds exposed to soil or water in tropical regions.
• Manage underlying conditions (e.g., diabetes) to reduce susceptibility.

When to Seek Professional Help

Seek immediate medical attention for unexplained fever, respiratory distress, or skin lesions after potential exposure to Burkholderia pseudomallei in endemic regions. Early evaluation is critical for severe or systemic symptoms.

Tips for Medical Coders

Document the clinical presentation (e.g., localized vs. disseminated) and any organ involvement to support the "other melioidosis" code (A24.3). Include exposure history or travel to endemic regions when available, as this may influence coding specificity. Ensure laboratory confirmation of Burkholderia pseudomallei is noted if available.